AU2009208610A1 - Modified release formulations of HMG CoA reductase inhibitors - Google Patents

Modified release formulations of HMG CoA reductase inhibitors Download PDF

Info

Publication number
AU2009208610A1
AU2009208610A1 AU2009208610A AU2009208610A AU2009208610A1 AU 2009208610 A1 AU2009208610 A1 AU 2009208610A1 AU 2009208610 A AU2009208610 A AU 2009208610A AU 2009208610 A AU2009208610 A AU 2009208610A AU 2009208610 A1 AU2009208610 A1 AU 2009208610A1
Authority
AU
Australia
Prior art keywords
rosuvastatin
pharmaceutically acceptable
modified release
formulation
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009208610A
Other languages
English (en)
Inventor
Satish Kumar Dalal
Srirupa Das
Ashish Ashokrao Deshmukh
Sheetal Kulkarni
Shirishkumar Kulkarni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of AU2009208610A1 publication Critical patent/AU2009208610A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009208610A 2008-01-30 2009-01-30 Modified release formulations of HMG CoA reductase inhibitors Abandoned AU2009208610A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN145/KOL/2008 2008-01-30
IN145KO2008 2008-01-30
PCT/IN2009/000069 WO2009095934A1 (en) 2008-01-30 2009-01-30 Modified release formulations of hmg coa reductase inhibitors

Publications (1)

Publication Number Publication Date
AU2009208610A1 true AU2009208610A1 (en) 2009-08-06

Family

ID=40638221

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009208610A Abandoned AU2009208610A1 (en) 2008-01-30 2009-01-30 Modified release formulations of HMG CoA reductase inhibitors

Country Status (8)

Country Link
US (1) US20110003837A1 (https=)
EP (1) EP2285353A1 (https=)
JP (1) JP2011510974A (https=)
AU (1) AU2009208610A1 (https=)
BR (1) BRPI0906728A2 (https=)
MX (1) MX2010008466A (https=)
WO (1) WO2009095934A1 (https=)
ZA (1) ZA201006157B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590161B2 (en) * 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) * 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
IL149422A0 (en) * 1999-11-03 2002-11-10 Smith Howard J & Ass Pty Ltd Oral pharmaceutical compositions for liver therapy
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
DE10209979A1 (de) * 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
US20050147620A1 (en) * 2004-01-05 2005-07-07 Karl Bozicevic Cinnamon formulation for reducing cholesterol and/or glucose levels
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid

Also Published As

Publication number Publication date
JP2011510974A (ja) 2011-04-07
MX2010008466A (es) 2010-10-25
US20110003837A1 (en) 2011-01-06
BRPI0906728A2 (pt) 2015-07-07
WO2009095934A1 (en) 2009-08-06
EP2285353A1 (en) 2011-02-23
ZA201006157B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
AU2007314795B2 (en) Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
RU2450804C2 (ru) КОМБИНИРОВАННОЕ ФАРМАЦЕВТИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩЕЕ ДИГИДРОПИРИДИНОВЫЕ БЛОКАТОРЫ КАЛЬЦИЕВЫХ КАНАЛОВ И ИНГИБИТОРЫ HMG-CоА-РЕДУКТАЗЫ
US8394845B2 (en) Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
JP2009500317A (ja) 放出特性改良医薬組成物およびその製造方法
KR20090091084A (ko) 방출성이 제어된 약제학적 제제
EP1904039A2 (en) Controlled release dosage formulation of duloxetine
AU2010242938A1 (en) Fixed dose drug combination formulations
AU2008288106A1 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
JP4457003B2 (ja) 放出制御医薬組成物
EP2319501B1 (en) Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
CN102014881A (zh) 药物制剂
JP2005519052A (ja) プラバスタチン医薬製剤及びその使用方法
US20110052683A1 (en) Pharmaceutical preparation for treating cardiovascular disease
US20110212175A1 (en) Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
US20210361582A1 (en) Colchicine salicylate derivatives and methods of treatment
US20110003837A1 (en) Modified release formulations of hmg coa reductase inhibitors
EP1663174A1 (en) Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent
KR20060118507A (ko) 유기 화합물을 포함하는 조성물
US20070160663A1 (en) Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent
KR101072600B1 (ko) 플루바스타틴을 포함하는 안정한 약제학적 조성물 및 그의 제조방법
WO2023002004A1 (en) Multiparticulate pharmaceutical composition
HK1216079B (en) Complex formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application